Clik here to view.
Therapeutic Licensing and M&A Deals
Licensing deals for therapeutic candidates in 2013 dropped to the lowest volume in at least eight years for deals with disclosed values totaling over $10M. Total upfront payments to biotechs were also...
View ArticleLooking Ahead to the 2014 BIO Investor Forum, Biotech IPO Hopefuls Continue...
As mentioned in Fierce Biotech, a new crop of biotech IPO hopefuls have recently thrown their hats into the ring. These three biotechs are targeting $175M in IPO cash, hoping to secure funding for...
View ArticleClik here to view.
Biotech CEOs Speak Out on JOBS Act Success
Enacted in April 2012, the Jumpstart Our Business Startups (JOBS) Act makes the pathway to capital formation more attainable for small biotechnology companies, clearing the way for American innovation...
View ArticleRoadblocks and Red Tape Block Search for Cures
Since its passage more than two years ago, the JOBS Act has spurred more than 110 biotech IPOs. And now the SEC is in the process of finalizing another important piece of the law that could further...
View ArticleBiotech Analyst Optimism: Price Targets Post-IPO
In a recent blog post, Bruce Booth of Life Sci VC, writes about the relationship between a forecasted price target of a biotech stock and its current share price. If biotech stocks hit their current...
View ArticleCFO Magazine: On the IPO On-Ramp
CFO Magazine highlighted the impact of the Jumpstart Our Business Startups (JOBS) Act on smaller companies aiming to obtain access to capital and the benefits of the JOBS Act by highlighting case...
View ArticleBlurred Lines: Investors Explain Their Re-Thinking of Traditional...
The recent expansion and acceleration of the biotech stock market has seen a new willingness and in some cases eagerness to pursue crossover investing in firms pre- and post-IPO. Venture capitalists...
View Article
